CGS.AX - Cogstate Limited

ASX - ASX Delayed price. Currency in AUD
1.02
+0.01 (+1.49%)
At close: 3:55PM AEDT
Stock chart is not supported by your current browser
Previous close1.00
Open1.02
Bid1.02 x 234500
Ask1.02 x 342500
Day's range0.99 - 1.03
52-week range0.79 - 1.39
Volume57,971
Avg. volume55,118
Market cap116.39M
Beta-0.24
PE ratio (TTM)-145.71
EPS (TTM)-0.01
Earnings dateN/A
Forward Dividend & YieldN/A (N/A)
Ex-dividend dateN/A
1y target est1.27
  • Business Wire11 days ago

    Cogstate Announces First U.S. Deployment of the Cognigram™ System at the University of Notre Dame

    BOSTON--(BUSINESSWIRE)-- The cognitive science company, Cogstate today announced the commercial deployment of its Cognigram™ digital cognitive assessment system at the University of Notre Dame. This placement represents the first Cognigram system commercial implementation in the United States, following the recent FDA notification that the Company can begin marketing the system in the U.S. “We are thrilled that the University of Notre Dame decided to adopt our cognitive testing solution immediately after the Cognigram system became available in the U.S.,” said Frank Cheng, President of Cogstate Healthcare.

  • Business Wire3 months ago

    Cogstate Receives Positive FDA Notification Regarding Medical Device Regulatory Submission

    The COGNIGRAM™ system is a digital cognitive assessment tool with self-administered assessment that can be completed both in-clinic and at-home. It is for prescription use, and is intended to aid healthcare professionals with an objective measurement of cognition for use in individuals aged 6 - 99 years old.

  • noodls11 months ago

    Executive Appointments

    Executive Appointments The text version of this document is not available at the moment. The original content was posted at original link . CogState Ltd. published this content on 24 November 2016 and ...

  • noodls11 months ago

    Appendix 3B New Issue Announcement

    Appendix 3B New Issue Announcement The text version of this document is not available at the moment. The original content was posted at original link . CogState Ltd. published this content on 24 November ...

  • noodls11 months ago

    Appendix 3B New Issue Announcement

    Appendix 38 Rule 2.7, 3.10.3, 3.10.4, 3.10.5 New issue announcement, application for quotation of additional securities and agreement Information or doc1u11e11ts 1101 available now 11111st be given to ...

  • noodls11 months ago

    Change of Director’s Interest Notice

    Appendix 3Y Change of Director's Interest Notice Appendix 3Y Change of Director's Interest Notice Rule 3.19A.2 Information or documents not available now must be given to ASX as soon as available. Information ...

  • noodls11 months ago

    Becoming a substantial holder

    Form 603 Corporations Act 2001 Section 671B Notice of Initial Substantial Holder To: Cogstate Ltd. ... This is an abstract of the original noodl. To continue reading this document, click here for the original ...

  • noodlslast year

    Appendix 3B New Issue Announcement

    Appendix 38 Rule 2.7, 3.10.3, 3.10.4, 3.10.5 New issue announcement, application for quotation of additional securities and agreement Information or documents not available now n1ust be given to ASX as ...

  • noodlslast year

    Cogstate enters into agreement with Clinical Ink

    ASX ANNOUNCEMENT 26 OCTOBER 2016 COGSTATE ENTERS INTO AGREEMENT WITH TECHNOLOGY COMPANY, CLINICAL INK, TO DELIVER ENHANCED TABLET-BASED NEUROPSYCHOLOGICAL ASSESSMENTS FOR CNS CLINICAL TRIALS Medical Technology ...